Literature DB >> 12761443

Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat.

Nicole S Wayman1, Belinda L Ellis, Christoph Thiemermann.   

Abstract

BACKGROUND: This study was designed to investigate the effects of simvastatin in a rat model of acute myocardial infarction. MATERIAL/
METHODS: Male Wistar rats were anesthetized (thiopentone sodium 120 mg/kg). After a thoracotomy, the left-anterior-descending coronary artery (LAD) was occluded (for 25 min) and reperfused (for 120 min). Area at risk (AR) was determined with Evans Blue dye and infarct size after staining of the area at risk with nitroblue tetrazolium.
RESULTS: In rats, which received the vehicle for simvastatin (10% DMSO, 1 ml/kg i.v. at 1 h prior to the occlusion of the LAD), occlusion of the LAD for 25 min followed by reperfusion for 2 hours resulted in an infarct size of 54 +/- 4% (n=7) of the AR. When compared with vehicle, administration of simvastatin (1 mg/kg i.v. bolus administration at 1 h prior to the onset of myocardial ischemia) caused a significant reduction in myocardial infarct size of 39%. LAD-occlusion and reperfusion caused a progressive fall in mean arterial blood pressure (when compared with sham-operated animals). Simvastatin had no significant effect on blood pressure.
CONCLUSIONS: The result indicates that simvastatin, an inhibitor of HMG-CoA reductase and a ligand of PPAR-a and PPAR-g, reduces the tissue necrosis associated with acute myocardial infarction. We propose that statins may be useful in conditions associated with ischemia-reperfusion of the heart and other organs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761443

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  6 in total

1.  Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke.

Authors:  Kama Z Guluma; Paul A Lapchak
Journal:  Brain Res       Date:  2010-07-29       Impact factor: 3.252

2.  Sub-proteomic fractionation, iTRAQ, and OFFGEL-LC-MS/MS approaches to cardiac proteomics.

Authors:  Chad M Warren; David L Geenen; Donald L Helseth; Hua Xu; R John Solaro
Journal:  J Proteomics       Date:  2010-04-12       Impact factor: 4.044

3.  Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel.

Authors:  J-L Zhao; Y-J Yang; C-J Cui; S-J You; R-L Gao
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

Review 4.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

5.  Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation.

Authors:  Xiang-Yang Zhu; Elena Daghini; Alejandro R Chade; Ronit Lavi; Claudio Napoli; Amir Lerman; Lilach O Lerman
Journal:  Life Sci       Date:  2008-10-21       Impact factor: 5.037

6.  Antiapoptotic effect of simvastatin ameliorates myocardial ischemia/reperfusion injury.

Authors:  Najah R Hadi; Fadhil Al-Amran; Maitham Yousif; Suhaad T Zamil
Journal:  ISRN Pharmacol       Date:  2013-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.